28 injections will be collected! 10 provinces to collect "lifting" price reduction tide

Recently, provincial belt procurement is in full swing, Qinghai officially announced 59 varieties, Shanxi 21 injection winning results determined, Shandong plans to start 40 varieties in July collection ..Minet data show that 40 band procurement varieties (105 standards) in 2019 in China's public medical institutions terminal sales of more than 1 billion yuan have 32; The best-selling drugs are in the listSo far, at least 10 provinces have carried out provincial drug shipment sourcingrecently, Shandong Provincial Health Insurance Bureau held a consultation meeting on 40 proposed quantity procurement varieties, discussed the specific bidding procurement rules, including quality stratification, price reduction requirements, winning regional selection, etc., the plan to start collection in JulyA fierce price war is coming!before, Shandong Province Medical Insurance Bureau on April 24 issued a notice, has been in accordance with the clinical use of large, high procurement amount, full competition principle, identified 40 centralized volume procurement of drug varietiesAccording to Minet.com, 32 of the 40 varieties (105 rules) with end-sales of more than 1 billion yuan in 2019 in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (china's public medical institutions)from the drug category, the digestive system and metabolic drugs involved in 15 varieties, 6 varieties for nervous system drugs, 4 varieties for blood and hematopoietic system drugs, anti-tumor and immunomodulators, cardiovascular system drugs, systemic hormone preparations (without sex hormones), miscellaneous and 3 varietiesAccording to Minet.com, sales of end-of-life digestive systems and metabolic drugs in public medical institutions in China in 2019 are second only to systemic anti-infective drugs40 band-purchased varieties of drug distribution
the net consistency evaluation database shows that of the 40 varieties purchased with volume in Shandong Province, the proportion of non-rated varieties reached 85%, only 6 over-rated varieties, respectively, the baritise metolol tablets, glioquine tablets, benzene sulfonysshun aquupamtom injection, doso tea injection, oshali platinum injection, and sodiumThe over-rated enterprises of these varieties have an advantage over other generic drug companies in biddingThese evaluated varieties will be divided into the first level with the original research drugs, expired patented drugs, reference formulations, Chinese drug list editing sets, as well as drugs exported to the United Kingdom, France, China, Canada, the United States, Australia and Japan6 overrated varieties
The 40 varieties purchased in Shandong Province, involving best-selling antihypertensive drugs, proton pump inhibitors, contrast agents, narcotic samines, anti-tumor drugs, antithrombotic drugs and so onIn terms of dosage form, 12 of the 40 varieties were oral preparations (oral chang-release dosage form, slow release control release dosage form) and 28 varieties were injectablessales of 40 strip-sourcing varieties in Shandong Province
According to Minet.com, 9 of the 12 oral preparations will have end-of-service sales of more than 1 billion yuan in 2019 in public medical institutions in China Among them, the sales of the left ammonia chlorine level oral regular release agent type (2.5mg, 5mg) is close to 5,028 million yuan, ShiHuida Pharmaceutical Group occupies 42.22% of the market share, the sales of the oral changxuan (10mg, 20mg) of Rebellaazole is close to 4.924 billion yuan, and Jichuan Pharmaceuticals occupies 37.07% of the market share 23 of the 28 injections, 23 will have end-of-the-world sales of more than 1 billion yuan in 2019 in public medical facilities in China Among them, omeprazole injections (20mg, 40mg, 60mg) close to 6.678 billion yuan, Osekang accounted for 41.58 percent of the market share, radorazole injection (40mg, 60mg, 80mg) sales of 6.197 billion yuan, Yangzijiang Pharmaceutical Group accounted for 29.60 percent of the market share It is worth noting that of the six proton pump inhibitors approved for sale in China, omeprazole, Lansorafen, pinotrazazole, Rebellaazole, Aiomeprazole are all on the list, and Epraazole is produced only by the Lizhu Group, which is not included in the collection due to insufficient competition 2019 China's public medical institutions terminal 28 injection sales TOP1 enterprises, Hengrui Pharmaceuticals, Yangzijiang Pharmaceutical Group, FesenYuskabi, Sanofi, Pfizer, Aspen have 2 varieties of sales first, Ruiyang Pharmaceuticals has 3 varieties of sales first Sales of iodized salsal intitators and ammonium ammonium benzene shun aquku were RMB3.685 billion and RMB 2,961 million, respectively, with Hengrui Pharmaceuticals accounting for 50.48 percent and 69.32 percent of the market share respectively Sales of iodine sea alcohol injections and protoprazole injections were RMB3.682 billion and RMB 6.197 billion, respectively, with Yangzijiang Pharmaceutical Group accounting for 51.92 percent and 29.60 percent of the market share, respectively has announced the volume of procurement varieties of the provinces into 2020, the national volume procurement continues to advance, the third batch of collection varieties list has been in the pipeline, provincial and local drug-belt procurement is also flowering everywhere Drug-belt procurement has entered the normal, "belt procurement as a principle, non-quantity procurement is the exception" recruitment policy system is being formed so far, at least eight provinces, including Guangxi, Hebei, Fujian, Hunan, Shanxi, Jiangxi, Shandong and Qinghai, have issued a list of concentrated tape purchase varieties, and Jiangsu, Yunnan and other provinces have announced that they will carry out provincial drug-belt procurement In addition, Sanming Alliance, Wuhan, Puyang, Jinhua and other districts / municipalities have also carried out local drug volume procurement Although the collection of drugs and quantities vary, but antimicrobials, proton pump inhibitors, slow disease drugs, etc have been on the list many times this year by the new crown pneumonia outbreak, the national health insurance control fee pressure intensified, provincial collection era accelerated to come, clinical use of large, high procurement amount, full competition for drugs bear the brunt On June 5, 2019, the National Health and Care Commission and other nine ministries jointly issued a letter to explicitly promote the development of non-over-rated drug tape procurement Previously, the national belt procurement varieties to consistency evaluation as the threshold, candidates for generic drug companies relatively few, but many varieties have fallen below the floor price, non-evaluated varieties of the volume of procurement due to fierce competition, in the provinces under the continuous exploration or will set off a wave of price reduction original title: 28 injections will be collected! Heng Rui, YangZijiang.. Heavyweight varieties are targeted, 10 provinces gather "lifting" price reduction tide